{
  "id": 4849229,
  "title": "Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest",
  "url": "https://urgent.news/2026/09/01/novartis-rhapsido-safer-than-rivals-phase-3-multiple-sclerosis-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T11:30:44.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/novartis-rhapsido-safer-than-rivals-phase-3-multiple-sclerosis-data-suggest/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Novartis’ BTK inhibitor Rhapsido has a chance of expanding from a chronic itch treatment to the multiple sclerosis market following wins in two identical Phase 3 trials. The pill significantly cut annualized relapse rates (ARR) ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}